The study compared the efficacy and safety of two initial treatment regimens for elderly patients with RAS/BRAF wild-type metastatic colorectal cancer: doublet chemotherapy with fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) plus panitumumab (Arm A) versus monochemotherapy with fluorouracil and leucovorin plus panitumumab (Arm B). A total of 183 patients aged 70 and up were randomly allocated to one of the two arms. The major goal was to achieve progression-free survival. The results revealed that both treatment arms met the objective median progression-free survival of at least 9 months, with Arm A achieving 9.6 months and Arm B achieving 9.0 months. The response rate in Arm A was 69% vs. 52% in Arm B. The median overall survival in both arms was almost the same.

To know more: About the original article click here.